These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 31400911)
1. Ten years of experience with herpes zoster vaccine in primary care- how attitudes and practices have changed and what it may mean for a new zoster vaccine. Guo A; Lindley MC; Hurley LP; Allen JA; Allison MA; O'Leary ST; Crane LA; Brtnikova M; Beaty BL; Kempe A; Dooling KL Vaccine; 2019 Sep; 37(37):5509-5512. PubMed ID: 31400911 [TBL] [Abstract][Full Text] [Related]
2. Primary care physicians' experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV). Hurley LP; Allison MA; Dooling KL; O'Leary ST; Crane LA; Brtnikova M; Beaty BL; Allen JA; Guo A; Lindley MC; Kempe A Vaccine; 2018 Nov; 36(48):7408-7414. PubMed ID: 30420121 [TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine. Grupping K; Campora L; Douha M; Heineman TC; Klein NP; Lal H; Peterson J; Vastiau I; Oostvogels L J Infect Dis; 2017 Dec; 216(11):1343-1351. PubMed ID: 29029122 [TBL] [Abstract][Full Text] [Related]
4. Public health impact of herpes zoster vaccination on older adults in Singapore: a modeling study. Oh H; Tan C; Williams C; Giannelos N; Ng C Hum Vaccin Immunother; 2024 Dec; 20(1):2348839. PubMed ID: 38804600 [TBL] [Abstract][Full Text] [Related]
5. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults. McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218 [TBL] [Abstract][Full Text] [Related]
6. Public health impact of herpes zoster vaccination on older adults in Hong Kong. Chan PKS; Wong MCS; Chan M; Ching K; Giannelos N; Ng C Hum Vaccin Immunother; 2023 Dec; 19(1):2176065. PubMed ID: 36854447 [TBL] [Abstract][Full Text] [Related]
7. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015. Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194 [TBL] [Abstract][Full Text] [Related]
9. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations. Prosser LA; Harpaz R; Rose AM; Gebremariam A; Guo A; Ortega-Sanchez IR; Zhou F; Dooling K Ann Intern Med; 2019 Mar; 170(6):380-388. PubMed ID: 30776797 [TBL] [Abstract][Full Text] [Related]
10. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme. van Oorschot DAM; Hunjan M; Bracke B; Lorenc S; Curran D; Starkie-Camejo H BMJ Open; 2019 May; 9(5):e025553. PubMed ID: 31061027 [TBL] [Abstract][Full Text] [Related]
11. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations. Parikh R; Widenmaier R; Lecrenier N Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643 [TBL] [Abstract][Full Text] [Related]
12. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany. Curran D; Van Oorschot D; Varghese L; Oostvogels L; Mrkvan T; Colindres R; von Krempelhuber A; Anastassopoulou A Hum Vaccin Immunother; 2017 Oct; 13(10):2213-2221. PubMed ID: 28708959 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. Le P; Rothberg MB JAMA Intern Med; 2018 Feb; 178(2):248-258. PubMed ID: 29297049 [TBL] [Abstract][Full Text] [Related]
14. Providers' lack of knowledge about herpes zoster in HIV-infected patients is among barriers to herpes zoster vaccination. Aziz M; Kessler H; Huhn G Int J STD AIDS; 2013 Jun; 24(6):433-9. PubMed ID: 23970744 [TBL] [Abstract][Full Text] [Related]
15. Post-marketing surveillance of 10,392 herpes zoster vaccines doses in Australia. Muttucumaru R; Lau CL; Leeb A; Mills DJ; Wood N; Furuya-Kanamori L Vaccine; 2024 May; 42(13):3166-3171. PubMed ID: 38677792 [TBL] [Abstract][Full Text] [Related]
16. Evaluating Physician Attitudes and Practices Regarding Herpes Zoster Vaccination. Tsui E; Gillespie C; Perskin M; Zabar S; Wu M; Cohen EJ Cornea; 2018 Aug; 37(8):947-951. PubMed ID: 29578865 [TBL] [Abstract][Full Text] [Related]
17. National survey of primary care physicians regarding herpes zoster and the herpes zoster vaccine. Hurley LP; Harpaz R; Daley MF; Crane LA; Beaty BL; Barrow J; Babbel C; Marin M; Steiner JF; Davidson A; Dickinson LM; Kempe A J Infect Dis; 2008 Mar; 197 Suppl 2():S216-23. PubMed ID: 18419400 [TBL] [Abstract][Full Text] [Related]
18. Studying physician knowledge, attitudes, and practices regarding the herpes zoster vaccine to address perceived barriers to vaccination. Elkin Z; Cohen EJ; Goldberg JD; Gillespie C; Li X; Jung J; Cohen M; Park L; Perskin MH Cornea; 2013 Jul; 32(7):976-81. PubMed ID: 23449488 [TBL] [Abstract][Full Text] [Related]
19. ATAGI Targeted Review 2022: Vaccination for prevention of herpes zoster in Australia. Huang YA; Li-Kim-Moy J; Jayasinghe S; Chiu C; Macartney K; Liu B; Burns P; Giles M; Crawford N Commun Dis Intell (2018); 2023 Apr; 47():. PubMed ID: 37106452 [TBL] [Abstract][Full Text] [Related]
20. Shingrix for Herpes Zoster: A Review. Shah RA; Limmer AL; Nwannunu CE; Patel RR; Mui UN; Tyring SK Skin Therapy Lett; 2019 Jul; 24(4):5-7. PubMed ID: 31339679 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]